evaluate the safety and immunomodulatory efficacy of Byolic CC supplement
Phase 1
Recruiting
- Conditions
- Immunomodulatory effect on healthy volunteers.
- Registration Number
- IRCT20240304061158N4
- Lead Sponsor
- Behpad Teb Iranian
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Health of volunteers
Exclusion Criteria
usage of immunosuppressive drugs, including cytotoxic drugs and corticosteroids, or any other drug (within 4 weeks before the start of the study) that may interfere with the supplement used in this study (or other herbal products)
drug and food allergies
pregnancy and lactation
cardiovascular, kidney, lung, liver, endocrine, hematological, neurological or psychiatric diseases, etc.)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method